SomaLogic has entered into a research agreement with Novartis to use its proprietary proteomics technology to help develop Novartis’ drug discovery.
“We are excited by this opportunity to work with Novartis’ world-class researchers to help them define robust biomarkers, validate novel drug targets, and even develop companion clinical diagnostics,” said Larry Gold, CEO of SomaLogic.
“”We believe that our technology is uniquely able to address the significant drug discovery and development challenges currently faced by biopharmaceutical companies.”
Terms of the agreement were not disclosed.
SomaLogic develops biomarker discovery and clinical diagnostics and is based in Boulder, Colorado.